Digital health companies create real clinical and operational value, then pass it to sales and marketing teams without a shared language for what it does or who it beats. The outcome is a pitch that varies by rep and a launch calendar without positioning behind it. We build the product marketing function that turns what you created into something a payer, provider, or benefits buyer can say yes to.
The Challenge
Your positioning was created for the last funding round, not today’s buyer
Most digital health companies write their positioning once, during a fundraise, aimed at investors rather than the clinical or benefits buyer who actually signs. That language survives untouched through three product releases and two go-to-market pivots. Sales reps quietly rewrite the pitch themselves because the official deck does not answer the questions prospects actually ask. By the time positioning gets revisited, the market has moved and competitors have claimed the ground you left open.
Every rep, deck, and one-pager tells a different version of what you do
Without a product marketer owning the narrative, positioning fragments across the org. Sales says one thing in a discovery call, the website says another, and the clinical team describes the product in terms a CFO cannot use in a business case. A health system procurement committee that hears three different value propositions from three different documents concludes the vendor has not figured out what it is selling. That inconsistency shows up as stalled deals, not lost ones – the prospect just stops responding.
Feature launches go live without a plan for how the market hears about them or why it should care
Engineering ships a new module, clinical validates it, and then nothing happens – no updated pitch, no enablement for the sales team, no announcement built around the buyer's problem instead of the feature list. Digital health buyers evaluate vendors on outcomes and evidence, not release notes, so a launch with no positioning behind it reads as a changelog entry, not news. Competitors with weaker products but disciplined launch motions win the deals your engineering effort should have earned.
Sales cannot address the objections that actually derail digital health deals
Clinical efficacy, data security, interoperability, and reimbursement pathway are the questions that stall enterprise health deals, and generic sales collateral rarely addresses them with the specificity a buying committee needs. Reps improvise answers to security and evidence questions because nobody built the competitive battlecards or objection-handling material that should exist before the deal starts. Every improvised answer is a chance to lose credibility with a buyer who has heard three other vendors answer the same question better.
How We Support You
We begin by rebuilding positioning from the buyer backward rather than the product forward. We interview your sales team, examine lost-deal notes, and speak with the people who assess and purchase digital health products – payers, provider systems, benefits leaders – to understand what they actually compare you with and what they need to hear before moving forward.
Next, we create the messaging architecture: a central narrative, role-specific value propositions for each role on a typical buying committee, and a competitive framework that positions you honestly against the alternatives your prospects are truly considering. This is not a rebrand.
We then translate that positioning into a repeatable launch motion. Each meaningful feature or product release receives a launch plan – what changes for the buyer, which proof supports the claim, what channels carry the message, and what sales needs in hand before the first post-launch call.
Sales enablement is where much of the embedded work takes place. We create the battlecards, objection-handling guides, and proof points that respond to the real questions digital health buyers raise about clinical evidence, security, and interoperability, then train the team to use them during a live deal.
To measure progress, we track message adoption in the field – whether reps are actually using the new positioning – together with win rates against named competitors and the specific objections appearing in lost deals. Product marketing in digital health does not appear as pipeline volume; it appears as fewer stalled deals and less time between the initial pitch and finalist status.
What sets this apart from hiring one in-house product marketer or assigning the work to a generalist agency is that we work as an embedded function with both the strategic perspective – positioning, competitive framework – and the operational discipline to deliver launches and enablement on a consistent cadence.
What we deliver
- Buyer-backward positioning built from sales interviews, lost-deal notes, and direct buyer research
- Messaging architecture with role-specific value propositions for clinical, IT, procurement, and finance buyers
- Honest competitive framework positioned against the alternatives your prospects actually evaluate
- Launch plans for every meaningful release, sequenced to the buyer's budget and planning calendar
- Sales battlecards and objection-handling guides addressing clinical evidence, security, and interoperability questions
- Message-adoption and win-rate tracking tied to named competitors and specific lost-deal objections
In digital health, product marketing is not simply a launch function – it is a deal-rescue function. The companies that resolve stalled pipeline are those that gave sales a clear answer to the security, evidence, and interoperability objections that actually kill deals, not those that redesigned the pitch deck.
Our Methodology
We deliver product marketing through a 90-day sprint that establishes the function and proves it against real pipeline. The first 30 days focus on diagnosis: we interview sales, analyze lost-deal notes and win-loss data, and speak directly with buyers to identify where the current positioning falls apart and which objections are truly killing deals. Days 30 through 60 rebuild the essential assets – positioning, messaging architecture, competitive framework, and the initial set of battlecards – and put them in front of sales for live use, rather than only a deck review. Days 60 through 90 center on the first launch delivered under the new positioning and measuring whether reps are actually applying the new material in deals.
Unlike a generalist marketing agency, we establish product marketing as an operating function embedded alongside your sales and clinical teams, not a one-time messaging project handed over as a document. In digital health, the objections that slow deals – clinical evidence, security posture, reimbursement pathway – are specific enough that generic B2B SaaS messaging frameworks fall short, so every asset is created from your real sales conversations, not a template. We continue running the function beyond the initial sprint because positioning and the competitive landscape evolve as the market changes and new competitors enter deals.
Our Approach
The first 30 days take place inside your sales process: we participate in deal reviews, study lost-deal and win-loss notes, and interview the reps pitching your product each week to understand where the current story falls apart. We also speak directly with a small group of buyers and near-miss prospects to hear how they explain the decision in their own language. Before changing anything, you receive a clear diagnosis of where positioning is costing you deals.
Days 30 through 60 are dedicated to building. We revise positioning and the messaging architecture, develop the competitive framework, and create the first set of sales battlecards and objection-handling materials. On your side, this requires access to sales leadership, several rep interviews, and review time from whoever is responsible for clinical or regulatory accuracy, because digital health claims must withstand scrutiny.
Days 60 through 90 bring the new positioning into the field. We execute the first launch using the new messaging, train the sales team to use the new battlecards, and begin tracking whether reps are actually applying the material in live deals. Most engagements last three to six months for the initial build, with product marketing continuing on retainer afterward because positioning and the competitive landscape require ongoing upkeep, not a one-time solution.
Our cadence includes a weekly working session with sales and marketing leadership, along with async reporting on message adoption and deal-level objections. We integrate with your existing sales rhythm – deal reviews, pipeline meetings – instead of treating product marketing as a side project detached from what is really happening in the pipeline.
- Consistent positioning across sales, website, and proposals
- Sales equipped to answer clinical, security, and interoperability objections directly
- Launches that land with a buyer-specific narrative instead of a feature list
- Fewer deals stalling on unanswered objections
If your digital health company needs product marketing leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
What does product marketing for a digital health company cost?
We price product marketing through a fixed monthly retainer based on the number of active launch initiatives, the level of sales enablement needed, and the amount of competitive and buyer research required during the diagnostic phase. A single-product company serving one buying committee is scoped differently than a company selling to payers, providers, and employers simultaneously.
How soon will we see results from a product marketing engagement?
The diagnostic phase identifies where positioning is costing you deals during the first 30 days. Updated positioning, messaging, and the initial battlecards reach sales by day 60, with the first launch using the new positioning running by day 90.
How does the product marketing team collaborate with our current sales and marketing staff?
We operate as an embedded team, not an outside vendor that delivers a deck. We join deal reviews and win-loss calls, speak with reps directly, and hand off battlecards and messaging alongside training instead of providing a document nobody reads.
How is Winston Francois different from a conventional product marketing agency?
A generalist agency creates a messaging deck and then moves on. We develop positioning from your real sales conversations and lost-deal data, remain embedded throughout launch and enablement work, and continue measuring whether reps use the material in actual deals.
How is ROI measured for a product marketing engagement?
We monitor message adoption – whether reps are genuinely using the new positioning in live deals – together with win rate against named competitors and the specific objections appearing in lost-deal notes before and after the engagement. Pipeline volume is not the scorecard; in digital health, product marketing appears as fewer deals stalled by unanswered objections and less time between pitch and finalist status.
What kind of digital health company is the best fit for this service?
This service is designed for digital health companies roughly within the 5M to 100M ARR range, beyond initial product-market fit, that sell to payers, providers, or employers through a buying process involving a committee and specific objections related to evidence, security, or reimbursement. It works best when sales leadership provides direct access to live deals and rep feedback.
